Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) ended Thursday session in green amid volatile trading. The shares closed up +9.48 points or 44.87% at $30.61 with 16.13 million shares getting traded. Post opening the session at $34.42, the shares hit an intraday low of $29.60 and an intraday high of $34.69 and the price vacillated in this range throughout the day. The company has a market cap of $803.12 million and the numbers of outstanding shares have been calculated to be 27.89 million shares.
Aerie Pharmaceuticals Inc (AERI) on September 16, 2016 announced that it has commenced a registered underwritten public offering of $50 million of shares of its common stock.
Cantor Fitzgerald & Co. is acting as the sole underwriter for the offering.
Aerie intends to use the net proceeds of the offering for general corporate purposes, including the complete funding of RhopressaTM commercialization costs, execution of clinical trials in Japan, commencement of construction of a manufacturing plant in Ireland and continuation of preclinical activity in support of its product pipeline, along with ongoing working capital requirements.
Shares of Boston Scientific Corporation (NYSE:BSX) ended Thursday session in green amid volatile trading. The shares closed up +0.51 points or 2.21% at $23.62 with 13.20 million shares getting traded. Post opening the session at $23.15, the shares hit an intraday low of $23.14 and an intraday high of $23.77 and the price vacillated in this range throughout the day. The company has a market cap of $31.48 billion and the numbers of outstanding shares have been calculated to be 1.36 billion shares.
Boston Scientific Corporation (BSX) develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems.